1.4 Chronic Disease States and Risk Factors for Critical Illness
Key Takeaways
- Chronic comorbidities such as COPD, heart failure, CKD, diabetes, and cirrhosis lower physiologic reserve and accelerate decompensation during acute insult.
- Frailty, malnutrition, immunosuppression, and advanced age increase both the risk of ICU admission and the likelihood of poor outcomes.
- Medication reconciliation of chronic therapies (beta-blockers, statins, antiplatelets, anticoagulants) is critical because abrupt discontinuation in the ICU precipitates withdrawal events and thrombosis.
- The BCCCP blueprint tests whether candidates can integrate chronic disease management into acute resuscitation decisions, including dose adjustments for organ dysfunction and continuation vs. withholding decisions.
Chronic Disease States and Risk Factors for Critical Illness
Critical illness rarely occurs in a vacuum. Most ICU admissions represent an acute insult layered on chronic disease burden, and the BCCCP Examination Content Outline (1A3, 1A4) explicitly tests the candidate's ability to recognize how chronic conditions modify presentation, complicate pharmacotherapy, and shape prognosis.
High-Prevalence Chronic Disease States in the ICU
| Chronic Disease | ICU-Specific Implication | Pharmacotherapy Consideration |
|---|---|---|
| COPD | Hypercapnic respiratory failure, beta-agonist and steroid load | Avoid non-selective beta-blockers in severe bronchospasm; watch for corticosteroid-induced hyperglycemia |
| Heart Failure (HFrEF/HFpEF) | Volume overload, low cardiac output, cardiorenal syndrome | Diuretic resistance, nesiritide, avoidance of negative inotropes in decompensated state |
| Chronic Kidney Disease | Hyperkalemia, uremic platelet dysfunction, fluid overload | Renal dose adjustment, avoidance of nephrotoxin stacking, CRRT drug dosing |
| Diabetes Mellitus | DKA/HHS, hyperglycemic crises, hypoglycemia risk | Insulin infusion protocols, glucose target 140-180 mg/dL in ICU, avoid sliding scale alone |
| Cirrhosis | Coagulopathy, hepatic encephalopathy, hepatorenal syndrome | Albumin for resuscitation, lactulose/rifaximin, avoid nephrotoxic NSAIDs, dose-adjust cleared drugs |
| Immunosuppression (HIV, transplant, chemo) | Opportunistic infection, neutropenic fever | Broad-spectrum coverage with antipseudomonal + anti-MRSA + antifungal coverage per risk |
Risk Factors for Critical Illness
Non-modifiable: Age >65, male sex, genetic predisposition (e.g., AAT deficiency in COPD, factor V Leiden in VTE), baseline frailty.
Modifiable: Smoking, obesity (BMI >40), alcohol use disorder, sedentary lifestyle, poor medication adherence, uncontrolled chronic disease, lack of vaccination (pneumococcal, influenza, COVID-19).
ICU-acquired risk factors: Nosocomial infection, deep vein thrombosis prophylaxis failure, stress ulcer bleeding, prolonged immobility causing ICUAW, delirium, and post-ICU syndrome.
Chronic Medication Continuity Decisions
The critically ill patient arrives on chronic medications that must be triaged: continue, hold, substitute, or modify dosing.
| Chronic Medication | ICU Decision | Rationale |
|---|---|---|
| Beta-blockers | Continue in most; do not stop abruptly | Tachycardia, hypertensive rebound, ischemia |
| Statins | Continue; consider high-dose in sepsis-associated ARDS | Pleiotropic anti-inflammatory effects; statin withdrawal increases mortality in sepsis cohorts |
| ACE inhibitors/ARBs | Hold in septic shock or AKI | Risk of AKI, hyperkalemia, hypotension |
| Antiplatelets (aspirin, P2Y12) | Continue post-PCI; hold for active bleeding | Stent thrombosis risk vs. bleeding |
| DOACs/warfarin | Hold; bridge with heparin if high VTE/stroke risk | Half-life prolongation in organ failure |
| Insulin | Convert to IV insulin infusion in critical illness | Subcutaneous absorption unreliable in shock |
| Levothyroxine | Continue; convert to IV (50-70% of PO dose) if GI dysfunction | Myxedema coma risk in hypothyroid patients |
Integrating Chronic Disease into ICU Triage
The BCCCP candidate must apply chronic disease data to acute decisions. Examples:
- COPD patient on home oxygen presenting with pneumonia: lower threshold for non-invasive ventilation, avoid excessive oxygen (CO2 retention), choose antibiotics covering pseudomonas if recent hospitalization.
- Cirrhotic with variceal bleeding: early octreotide, ceftriaxone for SBP prophylaxis, albumin-based resuscitation, avoid NSAIDs, watch for hepatorenal syndrome.
- Transplant patient on tacrolimus with septic shock: hold tacrolimus during acute kidney injury, check levels, broaden empiric coverage to include MRSA and resistant gram-negatives.
Risk Stratification Tools
- APACHE II/IV and SOFA incorporate chronic disease points.
- Charlson Comorbidity Index weights comorbidities and predicts 1-year mortality.
- Clinical Frailty Scale (CFS) predicts ICU and post-ICU outcomes; CFS >5 is associated with markedly higher mortality.
- ICU-acquired weakness (ICUAW) risk rises with prolonged immobility, hyperglycemia, sepsis, and neuromuscular blocker use; early mobility mitigates it.
Medication Reconciliation as a BCCCP Core Skill
The BCCCP Examination Content Outline explicitly tests medication reconciliation (1A4) because the transition into the ICU is a high-risk handoff for chronic therapies. The pharmacist must obtain the best possible medication history (BPMH) from family, outpatient pharmacy fill records, and prior discharge summaries—ICU patients are typically intubated or delirious and cannot self-report. Common reconciliation errors include:
- Omission: failing to restart chronic beta-blockers or statins, precipitating withdrawal, stent thrombosis, or statin-withdrawal mortality in sepsis.
- Duplication: restarting home carvedilol when a metoprolol infusion is running for atrial fibrillation rate control.
- Wrong dose: continuing a home renally cleared antibiotic dose after the patient develops AKI.
- Wrong route: continuing subcutaneous insulin in shock when absorption is unreliable.
Reconciliation must be repeated at ICU admission, ICU discharge to stepdown, and hospital discharge, with each transition documented. The BCCCP candidate should be able to construct a one-page reconciliation table listing each home medication, indication, ICU decision (continue/hold/substitute/modify), monitoring plan, and reassessment trigger.
Chronic Disease-Specific ICU Pharmacotherapy Pitfalls
| Chronic Disease | Pitfall | Consequence |
|---|---|---|
| COPD on chronic inhaled corticosteroid | Systemic steroid underdosing during exacerbation | Prolonged mechanical ventilation |
| Heart failure on sacubitril/valsartan | Holding ARNI without substituting ACE inhibitor | Worsening heart failure readmission |
| CKD on sevelamer or phosphate binders | Forgetting to hold during NPO periods | Hyperphosphatemia, hypocalcemia |
| Cirrhosis on propranolol for portal hypertension | Abrupt discontinuation | Variceal rebleeding |
| Transplant on mycophenolate | Holding indefinitely during sepsis | Acute rejection risk vs. infection risk balance |
Clinical Scenario
A 72-year-old male with COPD on home oxygen, HFrEF (EF 25%), CKD stage 3, and type 2 diabetes presents with septic shock from pneumonia. His home meds include carvedilol, lisinopril, furosemide, empagliflozin, insulin glargine, and aspirin. Which chronic medications should be held on ICU admission, and what acute adjustments are required?
Answer: Hold lisinopril (hypotension/AKI risk), empagliflozin (euglycemic DKA risk and AKI), and insulin glargine (unreliable subQ absorption in shock; convert to IV insulin infusion targeting glucose 140-180 mg/dL). Continue carvedilol (avoid withdrawal), furosemide (may need IV bolus given anasarca), and aspirin (no active bleeding). Empiric antibiotics should cover Pseudomonas given recent healthcare exposure.
Which chronic medication should generally be CONTINUED in a patient with septic shock to avoid rebound ischemia and tachycardia?
A cirrhotic patient presents with septic shock and requires fluid resuscitation. Which resuscitation fluid is preferred given the chronic disease state?